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EDITORIAL
The kidney and uric acid excretion in man
Hyperuricemia is the one biochemical alteration that is
common to all patients with gout. In primary gout, hyper-
uricemia has been attributed to an increase in the rate of
uric acid synthesis, a decrease in the renal excretion of uric
acid, or an alteration in both of these mechanisms [1].
Similarly, secondary hyperuricemia which results from the
administration of some drugs and occurs during the course
of certain disease states, has been attributed to a decrease in
uric acid excretion and/or to an increase in the rate of uric
acid synthesis. A number of specific hypotheses have been
formulated to explain the reduced clearance of uric acid
observed in these hyperuricemic states. In this editorial we
wish to discuss some of the evidence relevant to these pro-
posals.
According to present concepts the renal excretion of uric
acid in man is regulated by a three-component system: gb-
merular filtration, tubular reabsorption, and tubular se-
cretion [2]. It is usually assumed that virtually all urate in
the plasma is freely filterable at the glomerulus. Although
less than 5% of plasma urate is bound to plasma protein
at 37°C and isotonic conditions in vitro [3, 4], the relative
importance of urate binding to plasma protein has not
been evaluated in viva. Therefore, the assumption that
urate is freely filterable at the glomerulus must be tempered
by the possibility that subsequent studies may demon-
strate a significant binding of urate to plasma proteins
in vivo.
A number of studies in man have indicated a bidirectional
transport for uric acid within the nephron. Fractional ex-
cretion of uric acid, Curate/Cjnuijn x 100, is 7.6±2.4% in non-
gouty human subjects [5] indicating that uric acid must be
reabsorbed by the nephron. The first demonstration of uric
acid secretion in man came in 1950 when a young man with
a plasma urate of less than 0.6 mg/l0O ml was found to
have a urate/inulin clearance ratio of 1.46 [61. Uric acid
secretion has since been confirmed in normal man by the
demonstration of urate/inulin clearance ratios as high as
1.23 following urate loading, mannitol diuresis, and large
doses of probenecid [7]. From stop-flow studies in the dog
it has been suggested that uric acid is reabsorbed in the
proximal tubule and secreted in both the proximal and
distal tubule [8, 9]. In the only human study available, the
data indicated that uric acid was transported from the pen-
tubular space into the proximal tubular lumen [10]. In this
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experiment inulin (marker for glomerular filtration), PAH
(marker for proximal tubule), 42K (marker for distal tubule),
and uric acid-2-14C were given simultaneously by rapid
intravenous injection. Sequential urine samples were collect-
ed from the ureter and the concentration of each indicator
was determined. Uric acid appeared immediately after PAH
and before inulin. Although active versus passive transport
of uric acid could not be distinguished by these studies, the
above observation indicates that in man the proximal tubule
is permeable to uric acid. This study did not reveal a site for
uric acid secretion in the distal tubule.
The existence of bidirectional uric acid transport in man
seems certain from the above evidence. However, further
estimation of the relative contributions of filtration, tubular
reabsorption and tubular secretion to uric acid excretion
in normal man, as well as in hyperuricemic states, has been
difficult to obtain. Essentially all of the recent efforts to
further localize specific abnormalities in the renal transport
of uric acid in man, as related to each of the three compo-
nents described above, have been based on the pyrazinamide
suppression test [11]. This test has been used to estimate the
relative importance of uric acid reabsorption and secretion
in normal man under control conditions [11, 12], after the
administration of a number of drugs known to produce
hyperuricemia and hypouricemia [13], and in certain disease
states including primary gout [14], chronic lead intoxication
[15], renal failure [16], and Hodgkin's disease [17]. For ex-
ample, one major category of primary gout has been ascribed
to diminished renal uric acid secretion based on the pyra-
zinamide suppression test [14].
The premise upon which the pyrazinamide (PZA)
suppression test is based is that PZA selectively and totally
blocks uric acid secretion. Therefore, the quantity of uric
acid excreted following th administration of PZA is taken
to represent that portion of uric acid which escapes re-
absorption. The difference between uric acid excretion be-
fore and after PZA administration is regarded as the urinary
uric acid which arises from tubular secretion. Because of the
central role played by PZA in the evolution of many of the
recent concepts regarding uric acid transport in man, it is
reasonable to review the evidence relative to the critical
premise that the inhibitory effect of PZA on uric acid
secretion is both complete and selective.
PZA produces a greater than 95 % reduction of uric acid
excretion in the Dalmation Coach Hound, mongrel dog,
New World monkey and man [8,9, 11, 18, 19]. In addition,
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there is little doubt based on stop-flow studies in the dog
[9, 20] that PZA inhibits uric acid secretion in this species.
Due to the nearly complete absence of uric acid in the urine
after the administration of PZA in man, the assumption
was made that secretion must be completely inhibited. If
secretion of uric acid occurs exclusively at sites in the
nephron distal to the reabsorptive sites this would appear to
be a reasonable postulate. However, if uric acid secretion
occurs at a site in the proximal tubule in man as suggested
by the study cited above [10], it would be difficult to exclude
the possibility that reabsorption of secreted uric acid occurs
more distally in the tubule and that some degree of secretion
might persist in spite of PZA.
The assumption that the effect of PZA is limited to in-
hibition of secretion is also difficult to prove. For example,
the possibility that PZA is capable of enhancing uric acid
reabsorption in man cannot be excluded and in fact has
been proposed [18, 19]. Recent studies in the chimpanzee
point out the need to consider a second action of PZA in
addition to inhibition of uric acid secretion [18]. Curate!
ratios were compared before probenecid treatment,
after probenecid treatment, and again after infusion of
probenecid and PZA. Probenecid had a prompt uricosuric
effect with Cute/Cinuiin x 100 increasing from 9 to 40%.
When PZA was added to the infusion, without stopping
probenecid, there was a rapid reversal of the uricosuric
effect with Curate!CinuiinX 100 falling to less than 3%. If it
were not so conclusively established that probenecid in-
hibits uric acid reabsorption in the New World monkey,
one could postulate that probenecid exhibits its uricosuric
effect by enhancing secretion and PZA reversed the effect
of probenecid by inhibiting uric acid secretion. However,
under the circumstances one is led to conclude that PZA
has had an effect in addition to inhibition of secretion. This
effect of PZA could have been due to a blocking action of
PZA upon the inhibition of uric acid reabsorption produced
by probenecid, or as the authors propose, PZA could have
had an independent effect on increasing uric acid reab-
sorption [18]. Irrespective of the mechanism involved, these
studies point out the critical need to consider a second action
of PZA in addition to its effect on uric acid secretion,
especially when other drugs are involved.
Since it is not possible at the present time to state with
absolute certainty that the effect of PZA is a total and
selective inhibition of uric acid secretion, it seems unwise
to draw specific conclusions relevant to the mechanism by
which any drug alters the renal handling of uric acid based
on its effect in the presence and absence of PZA. In addition,
it would appear to be difficult to defend conclusions which
suggest specific abnormalities in uric acid transport in
various disease states that are based entirely on results of
of the pyrazinamide suppression test.
Although an analysis of bidirectional transport of uric
acid in man is difficult, recent studies linking uric acid and
sodium excretion may provide a different approach to
understanding one mechanism by which the kidney handles
uric acid. A number of physiological conditions are known
that affect sodium reabsorption and also alter uric acid
excretion. Several of these conditions are listed in Table I.
The first three conditions listed, salt restriction, protracted
and vigorous diuretic therapy, and diabetes insipidus, may
share the common feature of a contracted extracellular fluid
volume. Numerous studies have documented a correlation
between contracted extracellular fluid volume and an
increase in proximal tubular sodium reabsorption. The last
four conditions, diabetes insipidus, some types of hyper-
tension, angiotensin and norepinephine infusion, are all
associated with an increase in filtration fraction. Insofar as
changes in whole kidney filtration fraction can be used to
predict changes in sodium reabsorption, it might be anti-
cipated that an increase in filtration fraction could lead to
an increase in proximal tubular sodium reabsorption under
certain circumstances. Therefore, it does not seem un-
reasonable to suggest that the conditions listed in Table 1
may be associated with an increase in proximal tubular
sodium reabsorption. Each of these conditions is also
associated with a decrease in uric acid clearance.
In Table 2 the opposite situation with respect to sodium
and uric acid excretion is presented. A number of saline
loading experiments have been performed in man [21, 22,
28]. Cannon et al [28] have very clearly demonstrated that
hypertonic saline infusion produces an increase in Curate!
as well as CNa/Cjflul . In addition, these investigators
have shown that saline loading produces an increase in
fractional excretion of chloride, potassium, calcium and
magnesium [28], which is the reverse of that noted with
volume contraction [21]. In the cases of inappropriate
secretion of ADH reported by Mees et al [29] the fractional
excretion of sodium and uric acid were both increased in
untreated patients. When water was withheld, plasma
volume, body weight and bromide space all decreased in
these patients. The decrease in extracellular fluid volume
was associated with a decrease in Curate/Cjnuijn and a con-
comittant decrease in CNa/Cjfluljfl. Chronic renal disease is
another condition where sodium and uric acid reabsorption
have been associated. Animal studies have suggested that
sodium reabsorption per nephron is decreased in chronic
renal failure [31] and human studies have indicated that
uric acid excretion per nephron is increased [16].
The mechanism(s) by which changes in extracellular fluid
volume and/or filtration fraction may produce an alteration
in sodium reabsorption has been attributed to changes of
"physical factors" within the kidney. Possibly these effects
are mediated by hydrostatic and oncotic pressure changes in
the peritubular capillaries. Similarly, a natriuretic hormone
could explain the observed change in sodium excretion seen
under these experimental conditions. Whatever the me-
chanism(s) may be, the kidney appears to respond to
changes in extracellular fluid volume, and possibly to
changes of filtration fraction, in a relatively non-specific
manner, since tubular reabsorption of many solutes, in
addition to sodium, is affected [28]. It now appears that
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Table 1. Conditions associated with hyperuricemia or reduced renal uric acid clearance
Condition A Serum
urate
A Uric acid
clearance
A Extracellular
fluid volume
A Filtration
fraction
Predicted A
proximal tubular
sodium
reabsorptiona
Salt Restriction [21] 1 — 1
Diuretic Therapy without salt 1 I — I
replacement [21, 22, 23, 24]
Diabetes insipidus [25] 1 1 1 1 1
Hypertension [26] 1 1 — 1 1
Angiotensin infusion [27]
(without increased lactate or ketones) —
..
— I I
Norepinephrine [27]
(without increased lactate or ketones) — J. — I I
a Proximal tubular sodium reabsorption was not evaluated directly in the reported studies; the changes listed represent a prediction
from the observed changes in extracellular fluid volume and filtration fraction.
Table 2. Conditions associated with reduction in serum urate levels
Condition A Serum
urate
A Uric acid
clearance
A Extracellular
fluid volume
A Filtration
fraction
Predicted A
proximal tubular
sodium
reabsorption
Salt loading [21, 22, 28,]
.1. 1 I — I
Diuretic therapy with salt replacement [21, 22]
.J. I I — I
Inappropriate secretion of ADH [29] J I I — I
Pregnancy (early) [30J . I I — I
uric acid should be added to the growing list of solutes that
respond to changes in "physical factors".
Although the mechanism(s) responsible for the observed
decrease in uric acid excretion in some types of primary gout
is unknown [5, 14, 32], it is possible that the abnormality in
some patients with gout may involve an alteration in "phy-
sical factors" which affect both sodium and uric acid re-
absorption. The frequent association between gout and
hypertension becomes intriguing when considered in this
light. In such patients one could postulate a common ab-
normality in renal function that would result in an increase
in both sodium and uric acid reabsorption. This abnormality
could in turn be due to a primary difference in the response
of the kidney to some circulating or local factor, or perhaps
to a difference in the production or consumption of such a
factor. Alterations of reabsorption could summate with
inhibitory effects upon secretion as postulated by others
[26].
Summary. The purpose of this review has been to re-
evaluate some of the concepts relevant to the influence of
the kidney on uric acid excretion in man. The use of the
pyrazinamide suppression test, which has played a central
role in the development of a number of these concepts, has
been reconsidered and we conclude, from the data available,
that interpretations based on this test in man must be sub-
ject to reevaluation. In addition, evidence has been sum-
marized which suggests that tubular uric acid reabsorption
and tubular sodium reabsorption may be closely related in
some disease states.
Edward W. Holmes
William N. Kelley
James B. Wyngaarden
Durham, North Carolina
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